

**Lin BioScience, Inc. and Subsidiaries**  
**CONSOLIDATED BALANCE SHEETS**

**December 31, 2019 and 2018**

**(In Thousands of New Taiwan Dollars)**

	December 31, 2019		December 31, 2018	
	Amount	%	Amount	%
<b>ASSETS</b>				
<b>CURRENT ASSETS</b>				
Cash and cash equivalents	\$ 117,145	47	\$ 167,992	43
Financial assets at fair value through profit or loss - current	-	-	100,753	25
Other receivables	-	-	7,998	2
Current tax assets	96	-	131	-
Other current assets	<u>12,384</u>	<u>5</u>	<u>4,467</u>	<u>1</u>
Total current assets	<u>129,625</u>	<u>52</u>	<u>281,341</u>	<u>71</u>
<b>NON-CURRENT ASSETS</b>				
Property, plant and equipment	3,629	1	2,777	1
Right-of-use assets	7,992	3	-	-
Intangible assets	106,079	43	109,739	28
Refundable deposits	<u>1,397</u>	<u>1</u>	<u>1,482</u>	<u>-</u>
Total non-current assets	<u>119,097</u>	<u>48</u>	<u>113,998</u>	<u>29</u>
<b>TOTAL</b>	<u>\$ 248,722</u>	<u>100</u>	<u>\$ 395,339</u>	<u>100</u>
<b>LIABILITIES AND EQUITY</b>				
<b>CURRENT LIABILITIES</b>				
Financial liabilities at fair value through profit or loss - current	\$ 12	-	\$ -	-
Other payables	36,786	15	17,461	5
Lease liabilities - current	2,833	1	-	-
Corporate bonds payable	59,948	24	-	-
Other current liabilities	<u>1,234</u>	<u>1</u>	<u>389</u>	<u>-</u>
Total current liabilities	<u>100,813</u>	<u>41</u>	<u>17,850</u>	<u>5</u>
<b>NON-CURRENT LIABILITIES</b>				
Lease liabilities - non-current	<u>5,154</u>	<u>2</u>	<u>-</u>	<u>-</u>
Total liabilities	<u>105,967</u>	<u>43</u>	<u>17,850</u>	<u>5</u>
<b>EQUITY ATTRIBUTABLE TO OWNERS OF THE PARENT</b>				
Share capital	595,000	239	595,000	150
Capital surplus	125,430	50	125,278	32
Accumulated deficits	( 575,081 )	( 231 )	( 339,825 )	( 86 )
Other equity	( <u>3,538</u> )	( <u>1</u> )	( <u>2,964</u> )	( <u>1</u> )
Total equity attributable to owners of the Parent	141,811	57	377,489	95
<b>NON-CONTROLLING INTERESTS</b>	<u>944</u>	<u>-</u>	<u>-</u>	<u>-</u>
<b>TOTAL</b>	<u>\$ 248,722</u>	<u>100</u>	<u>\$ 395,339</u>	<u>100</u>

**Lin BioScience, Inc. and Subsidiaries**  
**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**  
**Years Ended December 31, 2019 and 2018**  
**(In Thousands of New Taiwan Dollars, Except Loss Per Share)**

	2019		2018	
	Amount	%	Amount	%
OPERATING REVENUE	\$ -	-	\$ -	-
OPERATING COSTS	-	-	-	-
GROSS PROFIT	-	-	-	-
OPERATING EXPENSES				
Marketing expenses	4,672	-	5,768	-
General and administrative expenses	40,203	-	45,834	-
Research and development expenses	193,346	-	104,002	-
Total operating expenses	238,221	-	155,604	-
LOSS FROM OPERATIONS	( 238,221 )	-	( 155,604 )	-
NON-OPERATING INCOME AND EXPENSES				
Other income	362	-	4,914	-
Other gains and losses	( 1,811 )	-	214	-
Finance costs	( 361 )	-	-	-
Total non-operating income and expenses	( 1,810 )	-	5,128	-
LOSS BEFORE INCOME TAX	( 240,031 )	-	( 150,476 )	-
INCOME TAX BENEFIT	( 4,775 )	-	( 11,960 )	-
NET LOSS FOR THE YEAR	( 235,256 )	-	( 138,516 )	-
OTHER COMPREHENSIVE INCOME (LOSS)				
Items that may be reclassified subsequently to profit or loss:				
Exchange differences on translating the financial statements of foreign operations	( \$ 603 )	-	( \$ 2,509 )	-
TOTAL COMPREHENSIVE LOSS FOR THE YEAR	( \$ 235,859 )	-	( \$ 141,025 )	-
NET LOSS ATTRIBUTABLE TO:				
Owners of the Parent	( \$ 235,256 )	-	( \$ 138,516 )	-
Non-controlling interests	-	-	-	-
	( \$ 235,256 )	-	( \$ 138,516 )	-
TOTAL COMPREHENSIVE LOSS ATTRIBUTABLE TO:				
Owners of the Parent	( \$ 235,830 )	-	( \$ 141,025 )	-
Non-controlling interests	( 29 )	-	-	-
	( \$ 235,859 )	-	( \$ 141,025 )	-
LOSS PER SHARE				
Basic and diluted	( \$ 3.95 )	-	( \$ 2.33 )	-